8-氨基-2-萘磺酸 | 6322-37-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 8-氨基-2-萘磺酸
• 英文名称: 1-Amino-naphthalin-7-sulfonsaeure
• 英文别名: Natrium-1-naphthylamin-sulfonat-(7)；sodium 8-aminonaphthalene-2-sulfonate；sodium 8-amino-2-naphthalenesulfonate；Sodium 8-aminonaphthalene-2-sulphonate；sodium;8-aminonaphthalene-2-sulfonate
• CAS: 6322-37-8
• 化学式: C₁₀H₈NO₃S*Na
• 分子量: 245.234
• InChiKey: GJYIHWVYSDKING-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.67
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2921450090

反应信息

• 作为反应物：
  描述：

  8-氨基-2-萘磺酸 在 hydroxide 、 sodium hydrogensulfite 作用下， 生成 8-羟基萘-2-磺酸
  参考文献：
  名称：

  Rieche,A.; Seeboth,H., Justus Liebigs Annalen der Chemie, 1960, vol. 638, p. 101 - 110

  摘要：

  DOI：

文献信息

• PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES
  申请人：Italfarmaco, S.A.

  公开号：EP1602644A1

  公开（公告）日：2005-12-07

  A naphthalenesulfonic acid or quinolinesulfonic acid of formula (I), wherein A is N or a CR8 formula group, where R8 is H, OH, NR10R11, independently from one another, where R10 and R11 represent H or C1-C6 alkyl or a group of formula NH-CO-R12, where R12 is C1-C6 alkyl or C6-C10 aryl; R1 and R2 represent H or SO3R9, independently from one another, where R9 is H, ammonium or a cation of an alkali or alkaline-earth metal; R3 is H or OH; and R4, R5, R6 and R7 represent H, an NR10R11 or NH-CO-R12 group, independently from one another; on the condition that (i) at least one of R1 or R2 is SO3R9, and (ii) at least one of R4, R5, R6 or R7 is an NR10R11 or NH-CO-R12 group, or their pharmaceutically acceptable salts; and a pharmaceutically acceptable excipient.

  一种具有化学式（I）的萘磺酸或喹啉磺酸，其中A为N或CR8配方基团，其中R8为H、OH、NR10R11，独立地，其中R10和R11分别代表H或C1-C6烷基或配方NH-CO-R12的基团，其中R12为C1-C6烷基或C6-C10芳基；R1和R2独立地代表H或SO3R9，其中R9为H、铵或碱金属或碱土金属的阳离子；R3为H或OH；R4、R5、R6和R7独立地代表H、NR10R11或NH-CO-R12基团；条件是（i）R1或R2中至少有一个为SO3R9，（ii）R4、R5、R6或R7中至少有一个为NR10R11或NH-CO-R12基团，或它们的药用可接受盐；以及药用可接受的赋形剂。
• Synthesis and photochemistry of 1,2-naphthoquinonediazide-(2)-n-sulfonic acid derivatives
  作者：J. Bendig、E. Sauer、K. Polz、G. Schopf、A. Koch

  DOI：10.1016/s0040-4020(01)85611-8

  日期：1992.1

  esterification. The synthesis of the corresponding 8-sulfonic acid ester 73 was not successful by this way. On photolysis the 1,2-naphthoquinonediazide-(2)-6- and -7-sulfonc acid phenyl esters (7c, 7d) form the corresponding (phenoxysulfonyl)-indenecarboxylic acid (10c, 10d) in the same manner like the known 5-sulfonic acid derivative 10b. Different from these isomers, on photolysis of the 4-sulfonic

  1,2-萘醌二叠氮化物-（2）-6-和-7-磺酸酯（7c，7d）首次从1-萘胺-6-和-7-磺酸（1c ，1d）分别通过Bucherer反应，亚硝化，还原，重氮化，磺酰氯，酯化。用这种方法不能成功地合成相应的8-磺酸酯73。在光解过程中，1,2-萘醌二叠氮化物-（2）-6-和-7-磺酸苯基酯（7c，7d）以已知的5相同的方式形成相应的（苯氧基磺酰基）-茚满羧酸（10c，10d）。 -磺酸衍生物10b。与这些异构体不同的是，对4-磺酸酯进行光解在图7a中，另外发生光化学诱导的酯裂解（λ＜320nm）。
• Pharmaceutical compositions containing sulphonic acid derivatives
  申请人：Banfi Tosi María Beatriz

  公开号：US20060160849A1

  公开（公告）日：2006-07-20

  A naphthalenesulfonic acid or quinolinesulfonic acid of formula (I), wherein A is N or a CR 8 formula group, where R 8 is H, OH, NR 10 R 11 , independently from one another, where R 10 and R 11 represent H or C 1 -C 6 alkyl or a group of formula NH—CO—R 12 , where R 12 is C 1 -C 6 alkyl or C 6 -C 10 aryl; R 1 and R 2 represent H or SO 3 R 9 , independently from one another, where R 9 is H, ammonium or a cation of an alkali or alkaline-earth metal; R 3 is H or OH; and R 4 , R 5 , R 6 and R 7 represent H, an NR 10 R 11 or NH—CO—R 12 group, independently from one another; on the condition that (i) at least one of R 1 or R 2 is SO 3 R 9 , and (ii) at least one of R 4 , R 5 , R 6 or R 7 is an NR 10 R 11 or NH—CO—R 12 group, or their pharmaceutically acceptable salts; and a pharmaceutically acceptable excipient.

  公式（I）中的萘磺酸或喹啉磺酸，其中A为N或CR8配方基团，其中R8为H，OH，NR10R11，独立地，其中R10和R11代表H或C1-C6烷基或配方为NH-CO-R12的基团，其中R12为C1-C6烷基或C6-C10芳基；R1和R2独立地代表H或SO3R9，其中R9为H，铵离子或碱金属或碱土金属阳离子；R3代表H或OH；R4、R5、R6和R7独立地代表H，NR10R11或NH-CO-R12基团；条件是（i）R1或R2至少有一个为SO3R9，且（ii）R4、R5、R6或R7至少有一个为NR10R11或NH-CO-R12基团，或其药学上可接受的盐；以及药学上可接受的赋形剂。
• Development of Potent and Selective Inhibitors of <i>ecto</i>-5′-Nucleotidase Based on an Anthraquinone Scaffold
  作者：Younis Baqi、Sang-Yong Lee、Jamshed Iqbal、Peter Ripphausen、Anne Lehr、Anja B. Scheiff、Herbert Zimmermann、Jürgen Bajorath、Christa E. Müller

  DOI：10.1021/jm901851t

  日期：2010.3.11

  ecto-5'-Nucleotidase (eN, CD73) plays it major role in controlling extracellular adenosine levels. eN inhibitors have potential its novel drugs, for example, for the treatment of cancer. In the present study, we synthesized and investigated a series of 55 anthraquinone derivatives as potential inhibitors of eN, I I of which are novel compounds and another I I of which had previously been described but have now been synthesized by all improved method. We identified several potent inhibitors of rat eN. The most potent compounds were 1-amino-4-[4-fluoro-2-carboxyphenylamino]-9, 10-dioxo-9, 10-dihydroanthracene-2-sulfonate (45, PSB-0952, K-i = 260 nM) and 1-amino-4-[2-anthracenylamino]-9, 10-dioxo-9, 10-dihydroanthracene-2-sulfonate (52, PSB-0963, 150 nM), with 52 being the most potent eN inhibitor described to date. Selected compounds were further characterized and found to exhibit a competitive mechanism of inhibition. Investigations of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the P2Y receptor subtypes P2Y(2), P2Y(4), P2Y(6), and P2Y(12) showed that compound 45 exhibited the highest degree of selectivity (> 150-fold).
• EP1994929A1
  申请人：——

  公开号：EP1994929A1

  公开（公告）日：2008-11-26